Plaque Psoriasis

Recent findings indicated that patients with new-onset psoriasis may see positive results from switching to secukinumab treatment.

This recent analysis highlighted an association between anxiety disorder and psoriasis in both children and adult patients.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, discuss implications of real-world data on the use of IL-23 inhibitors in treatment of plaque psoriasis for older patients.

Experts in dermatology discuss what patients to consider treating with deucravacitinib, as well as comment on the comparative safety and efficacy of other therapies.

Experts in dermatology discuss the importance of deucravacitinib being an expansion of oral treatment modalities for plaque psoriasis, as well as the long-term data.

In her interview with HCPLive, Armstrong spoke on new data presented at Fall Clinical Dermatology on bimekizumab, deucravacitinib, and upadacitinib.

Neal Bhatia, MD, discusses the impact of treatment mode of delivery on patient adherence and treatment selection for IL-23 inhibitors for plaque psoriasis.

Dermatology experts provide an overview of tildrakizumab, guselkumab, and risankizumab, agents approved for patients with plaque psoriasis.

The sex differences, as well as other demographic differences, between GPP patients were assessed in a recent research letter.

Experts in psoriasis examine the implications of long-term data for IL-23 inhibitors, especially in patients who have not responded to initial treatment of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, comment on potential safety concerns and adverse events regarding the use of IL-23 inhibitors as well as the long-term safety and efficacy of these therapies in plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, reviews deucravacitinib as an oral treatment for moderate to severe plaque psoriasis, describing its unique mechanism of action.

Douglas DiRuggiero, DMSc, PA-C, discusses factors that contribute to switching a patient with plaque psoriasis from a topical to a systemic agent.

In a summary of a symposium from the 2021 EADV Congress, the writers describe patients’ difficulties in living with psoriasis and adhering to treatments.

A recent study found that deucravacitinib saw positive results for moderate-to-severe adult plaque psoriasis patients.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss communicating with patients about their plaque psoriasis treatment options.

George Han, MD, PhD, discusses the practical considerations of escalating treatment to the use of traditional oral systemic agents such as apremilast or methotrexate.

Matthew T. Reynolds, PA-C, reviews the route of administration and dosing frequencies of current/approved IL-23 inhibitors tildrakizumab, guselkumab, and risankizumab for treatment of plaque psoriasis.

Matthew T. Reynolds, PA-C, reviews the mechanism of action of IL-23 inhibitors for the treatment of plaque psoriasis.

Darren West, MPAS, PA-C, reviews treatment failure as criteria for advanced practice providers to utilize a step-up treatment approach.

Andrea Nguyen, MS, PA-C, reviews commonly used therapies for the initial treatment of plaque psoriasis.

Neal Bhatia, MD, provides an overview of the spectrum of disease, topical choices, and transitioning to oral medications for the treatment of plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss the current role of topical therapy and the use of non-biologic oral systemic and standard therapies for plaque psoriasis treatment.

An expert nurse practitioner and a physician assistant examine the role of collaborative care in the management of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, highlight the importance of the initial patient/provider conversation in guiding treatment of plaque psoriasis.